Background-Anticoagulation control with warfarin, as assessed by the international normalized ratio (INR), is challenging.
A trial fibrillation (AF) is the most common cardiac arrhythmia, affecting ≈2.2 million Americans. 1 AF increases the risk of stroke ≈5-fold, and these strokes confer a 30-day mortality of 24%. 2, 3 The vitamin K antagonist warfarin greatly reduces the risk of stroke and is the most commonly used therapy to prevent stroke and stroke recurrence in patients with AF. [2] [3] [4] [5] Because of its variable dose-response relationship and narrow therapeutic window, warfarin requires frequent monitoring of its anticoagulant effect as reflected by the international normalized ratio (INR). 6 Percent of time in the therapeutic range (TTR; INR of 2.0-3.0) has been shown to correlate with stroke, major hemorrhage, and mortality. 5, 7, 8 
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To date, few studies have assessed the quality of warfarin management in routine clinical care outside of anticoagulation clinics. Quantification and evaluation of this metric are timely in that healthcare providers and organizations are increasingly faced with decisions on transitioning to more costly alternatives to warfarin that may provide better anticoagulation control such as dabigatran. In a recent study, the level of INR control by warfarin was shown to be a factor in determining the relative cost-effectiveness of dabigatran versus warfarin. 9 Maximal benefit of dabigatran was derived by centers in the lowest quartile of INR control (ie, TTR <57.1%). 9 Indeed, the quality of warfarin control may factor into the consideration to switch established patients prescribed warfarin to a novel anticoagulant such as dabigatran. 10, 11 The goal of our study was to provide a comprehensive and unbiased assessment of anticoagulation care in the United States by taking advantage of a unique data resource. Quest Diagnostics provides laboratory testing services to approximately half of the physician practices in the United States, with nearly 150 million patient encounters annually. The national scope of this database, coupled with the uniformity of the INR assay, provides an unprecedented opportunity to assess anticoagulation care in routine practice outside of hospitals (medical centers). We also examined the relationship of TTR to demographic features, physician case load, geographic region, duration of INR monitoring, and economic status. INR test results were extracted from the Quest Diagnostics Data Warehouse, along with patient demographics and insurance type. Age was categorized into 7 groups. Economic status was assigned by use of the median income from the 2007 US Census from the patient's home ZIP code. Median income was categorized into 5 ranges.
Methods

Study Design and Data Collection
This study was determined to be exempt from institutional review by the Western Institutional Review Board (Olympia, WA). To assess the impact of risk factors on TTR, we applied a β regression model with a probit link function using the "betareg" open-source statistical analysis package in R3.0.2. 13 The β regression model reflects the bounded property of our dependent variable (TTR is bounded by 0 and 1) and is particularly well suited for proportions data such as TTR.
The explanatory variables included sex, age, median income range, physician case load, HHS region, INR testing frequency, and length of testing. Overall model significance was assessed with the pseudo-R 2 and the log-likelihood ratio test. Coefficient estimates were evaluated with partial Wald statistics. Slope estimates measured in TTR units were imputed from the β regression coefficient estimates by use of the probability density function of the standard normal distribution evaluated at the mean of the fitted values.
Results
We identified 138 319 individuals with AF referred for testing by 37 939 unique physicians, providing a total of 2 683 674 INR results for analysis. The mean age of the patient population was 74 years; 55% were ≥75 years of age ( Table 1 ). The total observation time was 130 124 person-years. The average length of follow-up was 8.8 person-months (interquartile range, 4.2-19.4 months); 62% of the cohort had a study length of ≥6 months. (Figure 1 ).The overall mean TTR for individuals <45 years of age was 45.5% compared with 53.9% for those ≥75 years of age (P<0.001). The relationship between TTR and age persisted beyond the first 6 months of INR measurement. Important differences in TTR were also evident by sex. Within every age category, women had lower TTR (≈2%-3%) compared with men (P<0.001) and a higher frequency of INR testing (Figure 1 ). This relationship persisted beyond the initial 6-month period.
Time in the Therapeutic Range
Geographic Regio n
The influence of geographic residence on TTR is presented according to the 10 regions as defined by the HHS in Table 1 . In most regions, TTR increased by ≈10 percentage points when analyses were stratified by duration of INR testing. When we restricted our comparisons to regions with statistically robust representation (ie, excluding regions 8 and 10), the Northeast and Midwest regions (regions 1-3, 5, and 7) had higher mean TTR (53.3%-56.8%) than the Sun Belt states of the South, the Southwest, and the West Coast (regions 4, 6, and 9; mean TTR, 49.1%-52.8%). Region 1 (Connecticut, Massachusetts, New Hampshire, Rhode Island, and Vermont) had the highest mean TTR (57% overall, 60.0% for those individuals with ≥6 months in the study) and the highest mean frequency of INR testing (25.2 tests per year). Regions 1, 3, and 7 achieved a 58% threshold when analyses were restricted to patients with at least 6 months of INR data. 5
Patient Volume
As shown in Figure 2 , there was a direct relationship between the number of patients referred (physician case load) and TTR that was evident in both the inception and established periods of warfarin therapy. Of the 37 939 ordering physicians, nearly 95% ordered warfarin testing on <10 patients. A larger referral panel was associated with increased TTR, which may partly represent participation of non-hospital-based anticoagulation clinics.
Other Factors
An association between income and TTR was found, as previously reported by Rose et al. 14 Patients living in ZIP codes with the highest median incomes had higher mean TTR (P<0.001; Figure 3 ). This relationship persisted beyond the first 6 months of INR monitoring.
Multivariate Regression Model
Independent factors associated with TTR included length of the INR testing period, age, sex, physician case load, median income range, and HHS region ( Table 2 ). The pseudo-R 2 for the model is 0.09353, and the P value for the log-likelihood ratio test is <0.0001. Patients with a shorter INR testing period (<6 months) had a lower TTR than those with 6 to 24 months of testing (−4.3%; 95% confidence interval [CI], −4.6 to −4.0). Compared with patients in the ≥85-year age group, those in the 55-to 64-year age group had higher TTR (2.4%; 95% CI, 1.9-2.9) and those in the 35-to 44-year age group had lower TTR (−3.8%; 95% CI, −5.1 to −2.5). Similarly, women had lower TTR than men (−1.3%; 95% CI, −1.5 to −1.0). Compared with accounts composed of a large number of patients (>72), those with only 2 to 4 patients tested had lower TTR (−8.6%; 95% CI, −9.1 to −8.1). Patients who lived in the area with the lowest median income, defined as less than $30 000, had lower TTR than those in the highest income areas ($80 000 or greater; −5.6%; 95% CI, −6.3 to −4.9). Finally, compared with HHS region 1 (Connecticut, Massachusetts, New Hampshire, Rhode Island, and Vermont), region 6 (Arkansas, Louisiana, New Mexico, Oklahoma, and Texas) had lower TTR (−7.5%; 95% CI, −8.2 to −6.8)
In addition, we found a nonlinear association between INR testing frequency and TTR: INR testing frequency was positively associated with TTR among patients with <14 INR tests per year but inversely associated with TTR among those with 
Discussion
Quest Diagnostics provides laboratory testing services to approximately half of the physician practices in the United States. The quality control and uniformity of INR measurements, coupled with the national breadth of the AF population represented, provide a unique opportunity to assess the quality of anticoagulation management in office-based community practices. We purposefully excluded hospital-based accounts to enhance the representation of patients managed outside of hospital-based anticoagulation clinics. Of the 37 939 ordering physician practices in our study, nearly 95% ordered INR AF indicates atrial fibrillation; HHS, US Health and Human Services; LL, lower limit; TTR, time in the therapeutic range; and UL, upper limit. *The precision parameter (ϕ) for the β regression model is 3.34 (95% confidence interval, 3.32-3.36). The pseudo-R 2 for the overall model fit is 0.09353, and the log-likelihood ratio statistic is 12 407 (P<0.0001). Statistical significance of the coefficients is evaluated with the partial Wald statistics. Two variables (age group 45 to 54 years and region 10) were significant at the P<0.05 level. All other variables were significant at the P<0.001 level.
†The slope and approximate 95% confidence intervals are calculated in TTR units,%. They are derived from the coefficients of the β regression with a probit link function with the probability density function of the standard normal distribution evaluated at the mean of the fitted values [f(βx) = 0.3976].
‡The comparators for the categorical variables are study length ≥6 months, case load ≥72 AF patients, age ≥85 years; male sex; median income ≥$80 000; and HHS region 1 (CT, MA, NH, RI, and VT).
by guest on April 19, 2017 http://circ.ahajournals.org/ Downloaded from testing on <10 patients. Among the 138 319 individuals with AF evaluated, we found an overall mean TTR of 53.7%. The overall mean TTR for 9 of 10 HHS regions in the United States fell below the TTR threshold (58%-65%) reported to be necessary to achieve the efficacy of warfarin versus dual antiplatelet therapy. 5 Our TTR results are lower than the center-based TTR values reported from recent randomized trials: mean TTR for dabigatran versus warfarin, 64%; rivaroxaban versus warfarin, 55%; and apixaban versus warfarin, 62%. [15] [16] [17] When we restricted our analyses to the established warfarin subgroup, TTR improved to 58% (compared with 48% for individuals with <6 months of continuous INR data).
The stability of INR control has been shown to differ considerably between patients starting warfarin and established users in both clinical trials and observational studies. 18 The levels of anticoagulation control for the inception and established warfarin groups in our study are similar to those reported from a large Veterans Health Administration population. In that study of 100 anticoagulation clinics, the mean TTR values across all standard warfarin indications (not limited to AF) were 48% for the inception warfarin period and 61% for the established warfarin period. 14 The overall mean TTR in our study (53.7%) is also similar to the 54.5% reported for 8992 individuals with AF from Kaiser Permanente Southern California 19 but lower than the 62.5% reported from Kaiser Permanente Northern California. 20 Differences in the proportion of patients newly starting warfarin, the proportion of patients managed through anticoagulation clinics, and the health status of the AF populations studied may partly account for the disparity.
We also found younger age, female sex, and lower income to be independently associated with poorer anticoagulation control, similar to findings from the Veterans Health Administration. 21 The mechanisms underlying these associations are unknown but may be related to differences in treatment adherence, polypharmacy, health status, or underlying pathobiology. 21 The strong association between improved TTR and physician case load may reflect volume-related drug familiarity or better-organized warfarin management in the office setting or through a non-hospital-based anticoagulation clinic.
The novelty of our study lies in the availability and analysis of the national Quest Diagnostics database, which provides insight into the anticoagulation care provided outside of the hospital or medical center setting. The average length of follow-up was 8.8 person-months. To evaluate warfarin management most objectively, we required continuous serial INR measurements for inclusion in the study. Because individuals with gaps in care may represent a less healthy or less adherent population, it is possible that our results are an overestimate of TTR in practice.
A limitation of our study is the lack of prescription drug data. However, we believe the requirements for ≥2 months of serial INR measurements, ≥2 INR results of >1.2, and a diagnosis code of AF collectively minimized misclassification of warfarin exposure.
Our analysis of 138 319 individuals with AF represents the most comprehensive assessment of current anticoagulation care in routine practice in the United States to date and complements prior studies that focused on care rendered in organized health systems or anticoagulation clinics. Our results demonstrate suboptimal warfarin treatment for approximately half of the individuals with AF. Strategies to optimize stroke prevention for this population are urgently needed. Potential approaches include implementation of processes shown to improve TTR and consideration of transitioning appropriate candidates to newer oral anticoagulants. 10, 22, 23 
